Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

8.70 EUR-2.58 %10.11. klo 17.19
5,687 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-2.58 %
-5.43 %
-9.28 %
-7.45 %
-38.73 %
-41.81 %
+262.50 %
+62.92 %
-98.56 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
70.66M EUR
Turnover
23.13K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
17.08.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
3rd party
ShowingAll content types

Forum discussions
Device sale to a Nordic university hospital: nexstim.com Nexstim - Press-release
yesterday
by ghoul
31
Near the end there, Mikko had a bit of trouble holding back his smile. ”In 2026, We’re looking at at having a better year in both net sales wise and profitability. So that’s our outlook right now. An we’ve never been at the early October having such a large order backlog right now...
10/29/2026, 9:17 AM
by Kyhnykeisari
28
Inderes Nordic University Hospital Procures Nexstim NBS 6 System for Advanced... Press Release, Helsinki, 9 November 2026 at 9 AM (EEST)Nordic University Hospital Procures Nexstim NBS 6 System for Advanced Neuroscience ResearchNexstim Plc ("Nexstim" or "Company") has received...
yesterday
by Lovaskarhu
26
Now that the air is being let out of those AI hype stocks, Nexstim could be quite a smart place to put that cash from panic selling. The Trump administration has proposed significant cuts to NIH research funding, but the Democratic majority in Congress could make it difficult to ...
11/6/2026, 7:38 AM
by Kyhnykeisari
19
In Oulu, an easy treatment was discovered that could prevent memory disorders: “With good luck, a Nokia-scale thing” In Finland, a brain buzzer or washing machine is being developed to remove plaque. Tremble, Sinaptica!
11/3/2026, 5:04 PM
by Let's make some chimi change!
17
I personally listened with great interest to Mikko when he started talking about EEG. Nexstim clearly believes the TMS+EEG combo is the future and a competitive advantage when tightly integrated with each other. My personal guess is still that Nexstim and Bittium are discussing a...
10/29/2026, 12:27 PM
by AccionHombre
17
Personally, I am under the impression that the selling prices for the new-generation devices are higher than before. Support for my claim comes, for example, from this H1/2026 earnings webinar held on August 14, 2026: nexstim.wistia.com Nexstim IR-webinaari 2026 Tervetuloa Nexstimin...
11/4/2026, 9:03 AM
by Kyhnykeisari
11
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2.
2027

Annual report '26

Press release09.11.2026 klo 09.00

Nordic University Hospital Procures Nexstim NBS 6 System for Advanced Neuroscience Research

Nexstim
Press release04.11.2026 klo 15.00

Nexstim Plc appoints Ville Saarainen as new CTO

Nexstim
Press release29.10.2026 klo 09.00

Nexstim Receives Order for NBS 6 System from Finnish Hospital

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release27.10.2026 klo 10.00

Nexstim Plc: Share subscriptions based on stock options 2020 and 2023

Nexstim
Nexstim Q3'26: System deliveries point to a growth year
Analyst Comment26.10.2026 klo 11.40
by Antti Siltanen

Nexstim Q3'26: System deliveries point to a growth year

On volume, system sales are clearly ahead of the comparison period.

Nexstim
Press release23.10.2026 klo 09.00

Nexstim Plc Business Update Q3 2026

Nexstim
Press release14.10.2026 klo 09.00

Nexstim and Brainlab Advance Neuroscience Capabilities in Portugal with Installation at Hospital da Luz Lisboa

Nexstim
Third party research09.10.2026 klo 10.37

Nexstim: Conference feedback: Brainlab is set to scale NBS systems - NuWays AG Research

Paris MidCap conference feedback: Brainlab has the strategic fit and the installed base, to significantly scale Nexstim's NBS systems. Estimates unchanged. We remain with BUY and a PT of € 12.

Nexstim
Regulatory press release02.10.2026 klo 14.00

Nexstim Plc: Managers’ Transactions, Laine

Nexstim
Press release04.09.2026 klo 09.00

European University Hospital Orders Nexstim NBS 6 System

Nexstim
Press release03.09.2026 klo 09.00

Nordic Private Clinic Expands Use with Additional NBS 6 System

Nexstim
Third party research02.09.2026 klo 09.11

Nexstim: Stimulating growth with surgical accuracy; INITIATE with BUY - NuWays AG Research

Nexstim is a Finnish MedTech company and a global leader in navigated transcranial magneticstimulation (nTMS) technology. With nTMS, Nexstim helps (i) surgeons preserve patients' motor and speech cortices and (ii) clinicians treat neurological and psychiatric...

Nexstim
Press release02.09.2026 klo 09.00

US University Customer Purchases Nexstim NBS 6 for Research Purposes

Nexstim
Press release01.09.2026 klo 09.00

European Hospital Orders Nexstim NBS 6 System

Nexstim
Press release21.08.2026 klo 09.00

Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer

Nexstim
Regulatory press release20.08.2026 klo 13.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Press release19.08.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from New US Customer

Nexstim
Nexstim H1'26: Brainlab potential to be weighed later this year
Research17.08.2026 klo 10.09
by Antti Siltanen

Nexstim H1'26: Brainlab potential to be weighed later this year

Concrete evidence of the Brainlab collaboration's potential will be available during the rest of the year.

Nexstim
Regulatory press release14.08.2026 klo 09.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2026 (UNAUDITED)

Nexstim
Press release11.08.2026 klo 09.00

Notice of Nexstim Plc’s Half-Year Report H1 2026

Nexstim